Skye Bioscience, Inc. (SKYE)

Skye Bioscience Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Net Income	-37.5	-37.64	-19.48	-8.52	-6.56	1.05
Depreciation & Amortization	0.12	0.12	0.11	0.03	0	0
Share-Based Compensation	3.33	0.99	0.63	0.87	0.3	0.68
Other Operating Activities	19.44	22.58	5.99	1.14	0.2	-7.76
Operating Cash Flow	-14.6	-13.95	-12.74	-6.47	-6.05	-6.03
Capital Expenditures	-0.01	-0.01	-0.03	-0.09	-0.01	0
Acquisitions	2.22	6.61	5.24	0	0	0
Investing Cash Flow	2.21	6.6	5.21	-0.09	-0.01	0
Share Issuance / Repurchase	97.39	11.73	0	13.07	6.13	6
Debt Issued / Paid	4.76	4.71	-0.21	0	0.57	0.01
Other Financing Activities	-0.01	-0.01	0	0.01	-	-
Financing Cash Flow	102.14	16.44	-0.21	13.08	6.7	6
Net Cash Flow	89.75	9.09	-7.74	6.51	0.64	-0.02
Free Cash Flow	-14.61	-13.96	-12.77	-6.57	-6.06	-6.03
Free Cash Flow Per Share	-0.52	-1.99	-5.75	-4.04	-6.57	-11.15

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).